RecruitingNCT06794827

Early-access Avacopan in Real-world ANCA-associated Vasculitis

Evaluating Clinical Practice of Early Access Avacopan Treatment for ANCA-associated Vasculitis in European Countries


Sponsor

Leiden University Medical Center

Enrollment

100 participants

Start Date

Nov 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.


Eligibility

Min Age: 16 Years

Inclusion Criteria3

  • Established diagnosis of GPA or MPA
  • Treatment (initiation) with avacopan
  • Informed consent for use of medical data

Exclusion Criteria2

  • If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment
  • If a subject is below 16 years old

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Leiden University Medical Center

Leiden, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06794827


Related Trials